Axsome Therapeutics, Inc. (AXSM) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, and welcome to the Axsome Therapeutics Second Quarter twenty twenty six Earnings Conference Call. My name is Kevin, and I'll be your operator for today's call. At this time, all participants are in a listen only mode. Later, there will be a question and answer session and instructions will be given at that time. Please note this call is being recorded. I would now like to hand the call over to Ashley Dong, Senior Director of Investor Relations. Please go ahead, Ashley. Thank you. Good morning, everyone, and welcome to Axsome's second quarter twenty twenty six earnings conference call. Joining me today to discuss our results for the quarter are Doctor. Herriot Tabutto, Chief Executive Officer Nick Pizzi, Chief Financial Officer and Ari Maisel, Chief Commercial Officer, who will begin our call with prepared remarks. Mark Jacobson, our Chief Operating Officer and Hunter Murdock, our General Counsel, will also be available for Q and A. Before we begin, I encourage everyone to visit the Investors section of our website to find the press release and presentation for today's call. Please note that today's discussion includes forward looking statements regarding our financial performance, commercial strategy and operational plans, including research, development and regulatory activities. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that may cause actual results to differ materially. Please refer to our SEC filings, including our quarterly and annual reports for a description of these and other risks. You are cautioned not to rely on these forward looking statements, which are made only as of today, and the company disclaims any obligation to update such statements. And with that, I'll hand it ove...